Compugen Ltd. (CGEN)
1.46
0.05 (3.55%)
At close: Apr 02, 2025, 3:59 PM
1.45
-0.34%
After-hours: Apr 02, 2025, 06:33 PM EDT
3.55% (1D)
| Bid | 1.38 |
| Market Cap | 136.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.16 |
| PE Ratio (ttm) | -9.09 |
| Forward PE | -9.16 |
| Analyst | Buy |
| Ask | 1.63 |
| Volume | 105,828 |
| Avg. Volume (20D) | 652,208 |
| Open | 1.39 |
| Previous Close | 1.41 |
| Day's Range | 1.38 - 1.46 |
| 52-Week Range | 1.35 - 2.66 |
| Beta | 2.98 |
About CGEN
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients wi...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 11, 2000
Employees 74
Stock Exchange NASDAQ
Ticker Symbol CGEN
Website https://cgen.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CGEN stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 174.91% from the latest price.
Stock Forecasts
2 months ago · https://thefly.com
Compugen initiated with bullish view at Oppenheimer, here's whyCompugen +0.05 (+3.14%) AstraZeneca +0.44 (+0.66%) Gilead +0.7 (+0.79%)